Company profile: OrganOx
1.1 - Company Overview
Company description
- Provider of normothermic machine perfusion technology for donor livers via OrganOx metra, enabling functional assessment and preservation for up to 24 hours. Offerings support evaluation of liver function prior to transplantation, provide more flexible transplant logistics and surgery scheduling, and support complex or lengthy surgeries by extending preservation time.
Products and services
- OrganOx metra: Engineers a normothermic, donor-liver machine perfusion device that enables functional assessment and preservation of organs for up to 24 hours prior to transplantation
- Transplant Logistics with OrganOx metra: Delivers 24-hour-capable preservation of donor livers, offering more flexibility in surgery scheduling without compromising outcomes
- Functional Assessment with OrganOx metra: Offers pre-transplant evaluation of donor liver function using OrganOx metra, potentially increasing organ utilization by assessing donor livers before transplantation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OrganOx
XVIVO
HQ: Sweden
Website
- Description: Provider of organ perfusion, preservation, and assessment solutions for transplantation, including XPS for ex vivo lung perfusion and assessment; Liver Assist for hypothermic, normothermic, and sub-normothermic liver preservation; Kidney Assist Transport for hypothermic pulsatile perfusion of donor kidneys up to 24 hours; PERFADEX Plus for static cold storage of lungs; STEEN Solution for lung assessment; and XVIVO Academy training.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XVIVO company profile →
Oxford Immunotec
HQ: United Kingdom
Website
- Description: Provider of medical diagnostic tests based on patented T cell measurement technology, including T-SPOT.TB, an interferon gamma release assay for diagnosing latent TB infection and TB disease; T-SPOT.CMV for detecting cytomegalovirus infections; and T-SPOT.PRT for assessing immune responses to various pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Immunotec company profile →
Verici Dx
HQ: United States
Website
- Description: Provider of RNA signature-based diagnostics for kidney transplant patients, offering pre- and post-transplant prognostic tests—Clarava to predict early rejection risk and Tutivia to assess post-transplant rejection risk—and RNA Signature Tests that provide insights into immune response and transplant prognosis, while tracking patient records and the patient journey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verici Dx company profile →
Organ Transport Systems
HQ: United States
Website
- Description: Provider of portable, hypothermic, oxygenated preservation and transport technology for human organs, offering the LifeCradle HR durable perfusion unit and a complementing single-use organ chamber and fluid circuit kit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Organ Transport Systems company profile →
OSE Immunotherapeutics
HQ: France
Website
- Description: Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OSE Immunotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OrganOx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OrganOx
2.2 - Growth funds investing in similar companies to OrganOx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OrganOx
4.2 - Public trading comparable groups for OrganOx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →